Drug Trial Radar · NCT05347095
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
288
Actual
Start
Sep 27, 2022
Primary completion
Mar 25, 2027
Study completion Mar 25, 2027
Sponsor
- Lead sponsor
- Janssen-Cilag Ltd.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Apr 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn's disease and to assess the overall safety of guselkumab.
Conditions
- Fistulizing Crohns Disease
- Perianal Crohns Disease
Interventions
GuselkumabDrug
Guselkumab will be administered subcutaneously/IV infusion.
PlaceboDrug
Matching placebo will be administered subcutaneously/IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants who Achieve Combined Fistula Remission at Week 24Time frame: Week 24
Locations
154 sites in 23 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Yale University
New Haven, Connecticut
University of Miami
Miami, Florida
Gastroenterology Group Of Naples
Naples, Florida
AdventHealth Medical Group Blood & Marrow Transplant at Orlando
Orlando, Florida
Kansas University Medical Center
Kansas City, Kansas
University of Kentucky Chandler Medical Center
Lexington, Kentucky
University of Louisville
Louisville, Kentucky
Washington University School Of Medicine
St Louis, Missouri
Mount Sinai School of Medicine
New York, New York
Digestive Disease Specialists Inc
Oklahoma City, Oklahoma
Gastro One
Germantown, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
Tyler Research Institute, LLC
Tyler, Texas
Swedish Medical Center
Seattle, Washington
Flinders Medical Centre
Adelaide, Australia
St Vincent's Hospital - Melbourne
Fitzroy, Australia
Liverpool Hospital
Liverpool, Australia
Fiona Stanley Hospital
Murdoch, Australia
Royal Prince Alfred Hospital
Newtown, Australia
Royal Adelaide Hospital
North Terrace, Australia
Royal Melbourne Hospital
Parkville, Australia
Royal Perth Hospital
Perth, Australia
Mater Hospital
South Brisbane, Australia
Hopital Erasme
Brussels, Belgium
Ziekenhuis Oost-Limburg
Genk, Belgium
UZ Leuven
Leuven, Belgium
CHU Sart Tilman
Liège, Belgium
University of Alberta- Ziedler Ledcor Centre
Edmonton, Alberta, Canada
Nova Scotia Health Authority
Halifax, Nova Scotia, Canada
London Health Sciences Centre
London, Ontario, Canada
Mount Sinai Hospital
Toronto, Ontario, Canada
McGill University Health Centre
Montreal, Quebec, Canada
Nemocnice Ceske Budejovice a s
České Budějovice, Czechia
ISCARE a.s.
Prague, Czechia
Alexandria University Hospital 1
Alexandria, Egypt
Alexandria University Hospital
Alexandria, Egypt
National Hepatology and Tropical Medicine Research Institute
Cairo, Egypt
Ain Shams University Hospital
Cairo, Egypt
Cairo university
Giza, Egypt
Showing 40 of 154 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.